S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Important info on NVDA trade (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Important info on NVDA trade (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Important info on NVDA trade (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Important info on NVDA trade (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs

Zoetis Stock Price, News & Analysis (NYSE:ZTS)

$178.80
-1.41 (-0.78%)
(As of 11/27/2023 ET)
Compare
Today's Range
$178.48
$180.69
50-Day Range
$151.46
$182.00
52-Week Range
$140.76
$194.99
Volume
1.44 million shs
Average Volume
2.33 million shs
Market Capitalization
$82.09 billion
P/E Ratio
36.34
Dividend Yield
0.84%
Price Target
$216.29

Zoetis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
21.0% Upside
$216.29 Price Target
Short Interest
Healthy
0.68% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.67mentions of Zoetis in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$4.75 M Sold Last Quarter
Proj. Earnings Growth
10.54%
From $5.41 to $5.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

123rd out of 936 stocks

Pharmaceutical Preparations Industry

41st out of 437 stocks


ZTS stock logo

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

ZTS Stock News Headlines

Kristin C. Peck Sells 13,000 Shares of Zoetis Inc. (NYSE:ZTS) Stock
Zoetis Inc Class A
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano Sells 923 Shares of Stock
Expert Ratings for Zoetis
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Zoetis (NYSE:ZTS) Jumps on Q3 Beats
Zoetis Inc. (NYSE:ZTS) Q3 2023 Earnings Call Transcript
Q3 2023 Zoetis Inc Earnings Call
The Zoetis Inc (ZTS) Company: A Short SWOT Analysis
Zoetis Q3 Profit Rises; Updates FY Outlook
11 %
Zoetis (ZTS) Q3 2023 Earnings Call Transcript
Zoetis Announces Third Quarter 2023 Results
Earnings Outlook For Zoetis
Zoetis Inc Class A ZTS
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/1 Dividend
7/20/2023
Dividend Payable
9/01/2023
Ex-Dividend for 12/1 Dividend
10/31/2023
Last Earnings
11/02/2023
Today
11/27/2023
Dividend Payable
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/13/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
98978V10
Employees
13,800
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$216.29
High Stock Price Target
$260.00
Low Stock Price Target
$195.00
Potential Upside/Downside
+21.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$2.11 billion
Pretax Margin
34.38%

Debt

Sales & Book Value

Annual Sales
$8.08 billion
Cash Flow
$5.88 per share
Book Value
$9.45 per share

Miscellaneous

Free Float
458,425,000
Market Cap
$82.09 billion
Optionable
Optionable
Beta
0.83

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Zoetis was last updated on Tuesday, November 14, 2023 at 3:22 PM.

Pros

Here are some ways that investors could benefit from investing in Zoetis Inc.:

  • Zoetis Inc. is a leading animal health company that discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products.
  • The company operates in the pharmaceutical preparations industry, which is a stable and growing sector.
  • Zoetis Inc. has a diverse product portfolio that caters to both livestock and companion animals, including dogs, cats, and horses.
  • The recent FDA approvals of Zoetis' Librela injection for the treatment of osteoarthritis pain in dogs and Apoquel chewable tablets for dogs with allergic and atopic dermatitis demonstrate the company's commitment to innovation and addressing unmet needs in the animal health market.
  • The global animal health market is projected to reach $60.9 billion by 2027, indicating significant growth potential for Zoetis Inc.

Cons

Investors should be bearish about investing in Zoetis Inc. for these reasons:

  • The stock price of Zoetis Inc. is subject to market fluctuations and may be influenced by various factors such as economic conditions, competition, and regulatory changes.
  • Investing in the pharmaceutical industry carries inherent risks, including the potential for clinical trial failures, regulatory hurdles, and patent expirations.
  • While Zoetis Inc. has a strong market presence, it faces competition from other animal health companies, which could impact its market share and profitability.
  • The COVID-19 pandemic has had both positive and negative effects on the animal health industry, and the long-term impact on Zoetis Inc.'s business remains uncertain.
  • Investors should carefully consider their investment goals, risk tolerance, and conduct thorough research before making any investment decisions related to Zoetis Inc.














ZTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price target for 2024?

6 Wall Street research analysts have issued 12-month price targets for Zoetis' stock. Their ZTS share price targets range from $195.00 to $260.00. On average, they expect the company's stock price to reach $216.29 in the next year. This suggests a possible upside of 21.0% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2023?

Zoetis' stock was trading at $146.55 at the beginning of the year. Since then, ZTS stock has increased by 22.0% and is now trading at $178.80.
View the best growth stocks for 2023 here
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ZTS earnings forecast
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its quarterly earnings results on Thursday, November, 2nd. The company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.01. The business had revenue of $2.15 billion for the quarter, compared to analysts' expectations of $2.17 billion. Zoetis had a trailing twelve-month return on equity of 52.22% and a net margin of 27.24%.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Thursday, October 12th. Stockholders of record on Wednesday, November 1st will be paid a dividend of $0.375 per share on Friday, December 1st. This represents a $1.50 annualized dividend and a dividend yield of 0.84%. The ex-dividend date is Tuesday, October 31st.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.50 per share and currently has a dividend yield of 0.83%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 30.49%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 25.08% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Who are Zoetis' major shareholders?

Zoetis' stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (2.67%), FMR LLC (1.77%), Northern Trust Corp (1.34%), Polen Capital Management LLC (1.12%), Bank of New York Mellon Corp (0.87%) and Massachusetts Financial Services Co. MA (0.81%). Insiders that own company stock include Glenn David, Gregory Norden, Heidi C Chen, Kristin C Peck, Robert Edward Kelly, Robert J Polzer, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
This page (NYSE:ZTS) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -